INVESTOR RELATIONS

(TSXV:VPT, OTC:VPTDF)

Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools.  It sells its products worldwide.
VMS+3.0 FOR 2D ECHO B-97.png
Green Gradient Technology Professional_B
CAPITAL STRUCTURE

Shares Outstanding        155M
Shares Fully Diluted        178M
Recent Share Price         CDN$.53 (US$.42)
52-Week Range              CDN$.07-.68
Market Cap                      ca. CDN$90M (USD$70M)
Debt                                 None
Cash                                $10M
Liquidity                           CDN$1.0M/day
                                        USD$0.75M/day

Symbol:    TSX-V: VPT    &    OTC: VPTDF

Green Gradient Technology Professional_B
OUR STRATEGY

Staying true to our story, Ventripoint Diagnostics Ltd. continues to be dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians,  and most importantly improves the clinical experience for our youngest to oldest patient.   

Blue%20Marketing%20Start-up%20Business%2

Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.

VMS+ could eventually help treat our most loyal best friend.

EXPLORING NEW FRONTIERS FOR VMS+
Read More
LATEST PRESS RELEASES
Green Gradient Technology Professional_B

November 22, 2021

November 9, 2021

Ventripoint Provides Corporate Update on Market Adoption of VMS+ Whole-heart Analysis System

Ventripoint Passes Audit of Manufacturing Facility for Canadian and US Markets

November 29, 2021

Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans

November 22, 2021

Ventripoint Provides Corporate Update on Market Adoption of VMS+ Whole-heart Analysis System

November 9, 2021

Ventripoint Passes Audit of Manufacturing Facility for Canadian and US Markets

Green Gradient Technology Professional_B
LATEST EVENTS

AUG
09

Ventripoint Annual General Meeting 2021

JUN
22

Ventripoint Diagnostics Update with George Adams and Alvira Macanovic

JUN
10

Ventripoint Diagnostics Update and Q&A with George Adams, Alvira Macanovic and Dr. Mark Swaim

MAY
26

Ventripoint Diagnostics Update and Q&A with Dr. George Adams

FEB

11

Ventripoint CEO interviewed on TraderTV Live

Ventripoint CEO interviewed by Torrey Hills Capital

Green Gradient Technology Professional_B

MAR

25

FEB

11

Ventripoint CEO interviewed by Torrey Hills Capital

MAY

13

BioPub/Torrey Hills Capital  Zoom Webinar

Topic: Ventripoint: Bigger and Better, with CEO Dr. George Adams

APR
28

Ventripoint Diagnostics Update - Overview & Update on GE Health Collaboration

APR

25

Ventripoint Diagnostics Update

MAR

25

Ventripoint CEO interview on BioPub

FEB

11

Ventripoint CEO interviewed on TraderTV Live

FEB

04

Ventripoint CEO interviewed by Torrey Hills Capital

Green Gradient Technology Professional_B
INVESTOR RELATIONS TEAM
Jonathan Robinson
Oak Hill Financial Inc.
(416) 669-1001
JRobinson@oakhillfinancial.ca
Adrian Sydenham
MarketSmart Communications Inc.
(877) 261-4466
Info@marketsmart.ca

We will be sending you our updates and news releases.
 

Unsubscribe

If you no longer want to receive Ventripoint's press releases, you can unsubscribe at any time.

Subscribe for Investor Updates